These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21210910)

  • 1. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review.
    Kaplan SA; Roehrborn CG; Abrams P; Chapple CR; Bavendam T; Guan Z
    Int J Clin Pract; 2011 Apr; 65(4):487-507. PubMed ID: 21210910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of an α
    Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
    Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia.
    Chapple C
    Curr Opin Urol; 2010 Jan; 20(1):43-8. PubMed ID: 19875964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial.
    Kim TH; Jung W; Suh YS; Yook S; Sung HH; Lee KS
    BJU Int; 2016 Feb; 117(2):307-15. PubMed ID: 26305143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
    Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
    Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
    Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
    Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
    Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
    BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients - a network meta-analysis.
    Su YT; Chen HL; Teoh JY; Chan VW; Wu WJ; Lee HY
    BMC Urol; 2023 Oct; 23(1):154. PubMed ID: 37789333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis.
    Lenfant L; Pinar U; Roupret M; Mozer P; Chartier-Kastler E; Seisen T
    J Urol; 2023 Feb; 209(2):314-324. PubMed ID: 36395428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.